What colistimethate sodium dosing regimen should be used in a patient with an estimated glomerular filtration rate of 33 mL/min?

Colistimethate Sodium Dosing at GFR 33 mL/min

For a patient with GFR 33 mL/min, administer colistimethate sodium at 2.5 mg colistin base activity (CBA) once daily or divided into 2 doses per day, based on FDA-approved dosing for moderate renal impairment. 1

Dosing Algorithm by Renal Function

The FDA label provides clear guidance stratified by creatinine clearance 1:

• Your patient (GFR 30-49 mL/min - Moderate impairment): 2.5 mg/kg CBA once daily OR divided into 2 doses per day
• Mild impairment (CrCl 50-79 mL/min): 2.5-3.8 mg/kg divided into 2 doses per day
• Severe impairment (CrCl 10-29 mL/min): 1.5 mg/kg every 36 hours
• Normal function (CrCl ≥80 mL/min): 2.5-5 mg/kg divided into 2-4 doses per day

Critical Dosing Considerations

Use ideal body weight for obese patients when calculating the dose 1. This is essential as colistin distributes poorly into adipose tissue, and using actual body weight in obese patients leads to overdosing and increased nephrotoxicity risk.

Target plasma concentration: The therapeutic target is an average steady-state plasma concentration (Css,avg) of 2 mg/L 2. However, achieving this target is challenging in patients with moderate renal impairment—research shows that standard dosing often results in subtherapeutic levels (Css,avg <2 mg/L in 83.3% of CKD patients) 3.

The Dosing Dilemma at This GFR Level

You face a significant therapeutic challenge: Recent pharmacokinetic studies demonstrate that FDA-recommended doses for patients with CrCl 30-49 mL/min are approximately half of what contemporary research suggests is needed 3. In one study, the mean administered dose was 3.36 mg/kg versus the recommended 6.07 mg/kg (p<0.001), yet clinical cure rates remained acceptable at 72.9% 3.

The evidence reveals conflicting priorities:

• Lower doses (per FDA label): Reduce nephrotoxicity risk but may be subtherapeutic
• Higher doses (per recent research): Better target attainment but increased nephrotoxicity risk (>32.51% when Css,avg approaches 4 mg/L) 4

Practical Management Strategy

Start with FDA-recommended dosing (2.5 mg/kg once daily or divided BID) 1, then:

1. Measure MIC of the pathogen: If MIC ≥1 mg/L, probability of target attainment drops significantly (<66.56%) even with standard dosing 4

2. Consider therapeutic drug monitoring (TDM): Measure colistin plasma concentrations after 3-4 days of therapy to ensure Css,avg ≥2 mg/L 2, 3

3. Monitor renal function closely: Check creatinine and GFR within 48-72 hours of initiation and every 2-3 days thereafter. Worsening renal function occurs in approximately 34% of CKD patients but is reversible in about half 3

4. Strongly consider combination therapy: Given the high likelihood of subtherapeutic monotherapy at this GFR level, colistin should be used as part of a highly active combination regimen, especially for organisms with MIC ≥1 mg/L 5

Administration Route

Intravenous administration is preferred over intramuscular in critically ill patients. Use either:

• Direct intermittent: Inject half the daily dose over 3-5 minutes every 12 hours
• Continuous infusion: Inject half the dose over 3-5 minutes, then infuse the remaining half over 22-23 hours 1

Common Pitfalls to Avoid

• Don't use actual body weight in obese patients—this is the most common dosing error
• Don't assume standard dosing achieves therapeutic levels—80% of CKD patients have subtherapeutic concentrations without TDM 3
• Don't use colistin monotherapy for high-MIC organisms (≥1 mg/L) in patients with preserved renal function—target attainment is inadequate 4, 5
• Don't forget to adjust for dialysis: If the patient requires intermittent hemodialysis, use the moderate impairment dose on non-dialysis days 2